Drug Database
ME

meningococcal A conjugate vaccine (MenAfriVac)

✓ Approved

Serum Institute of India Pvt. Ltd. · Cell-based Therapies · Cell-based Therapies

What is meningococcal A conjugate vaccine?

meningococcal A conjugate vaccine is a cell-based therapies developed by Serum Institute of India Pvt. Ltd.. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesMenAfriVac
CompanySerum Institute of India Pvt. Ltd.
Drug ClassCell-based Therapies, Vaccine
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Serum Institute of India Pvt. Ltd.

Therapeutic Indications

meningococcal A conjugate vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsMeningococcal bacteraemia✓ Approved

Related Research Articles

PubMedAdvances in virology2026-09-20

Comparative Sequence Analysis of the Envelope Gene of Kyasanur Forest Disease Virus Vaccine Strain With Currently Circulating Field Strains.

Kaje Keerthi K, Marinaik Chandranaik B CB, Gomes Amitha Reena AR, Rizwan Apsana A et al.

The present study was undertaken with the objective of performing comparative sequence analysis of the envelope (E) gene of Kyasanur forest disease virus (KFDV) vaccine strain P9605 with the circulating field strains. The study was taken up as the currently used KFDV vaccine strain, KFDV P9605, was isolated in the 1960s. For this study, we designed two sets of primers targeting the complete amplification of the E gene of KFDV. The sequencing was performed by the Sanger method, and the deduced sequence of the vaccine virus was deposited in GenBank with accession number PX067005. This sequence obtained for the vaccine virus was aligned and compared with sequences of GenBank-deposited circulating field strains. We also performed comparative sequence analysis of the Kyasanur forest disease (KFD) vaccine seed virus having passaged twice in mouse brain with the vaccine seed virus passaged six times in mouse brain to investigate whether multiple passages in mouse brain will lead to genetic mutation in the immunologically important E gene. The phylogenetic analysis revealed seven amino acid mutations in the field strains at positions A123T, S158N, D178E, D239N, A313S, M429I, and G479A when compared with the vaccine strain. We did not find any mutations at the critical fusogenic segment (residues 98-113) in the E gene of currently circulating field strains compared to the vaccine seed virus. The study found no genetic variations in the E gene of the KFD virus passed two times and passed six times in mouse brain. We performed SWISS-MODEL homology modeling, AlphaFold protein analysis, and Ramachandran plot analysis to study the E protein structures and stability. The observations made in this study suggest slow evolutionary drift and conserved structural stability of the envelope gene of KFDV ever since its emergence 7 decades ago; however, the functional implications of these amino acid substitutions need further studies on their roles in viral infectivity, transmission, and impact on immunity.

PMID 42763584
Read full article →
PubMedInternational journal of nanomedicine2026-09-20

Biotinylated ε-Polylysine-Cyclodextrin-Coated Mesoporous Silica Nanoparticles for Targeted pH-Responsive Baicalin Delivery.

Liao Rongqiang R, Ruan Yi Y, Zhang Ke K, Liu Maoxia M

Baicalin (BAI) is a natural flavonoid with antitumor potential, but its poor water solubility and low bioavailability limit clinical use. Mesoporous silica nanoparticles are promising drug carriers due to their large surface area and tunable pore structure, yet premature drug leakage remains a key challenge. A multifunctional nanoplatform, designated as BPCD@BAI@BMSN, was constructed to enable efficient baicalin loading, pH-responsive gated release, and biotin-mediated active tumor targeting. A novel biotin-ε-polylysine-cyclodextrin (BPCD) conjugate was synthesized via EDCI/NHS coupling and characterized by NMR and GPC. Hollow mesoporous silica nanoparticles (BMSN) were prepared by the Stöber method, surface-modified with benzothiazole. The BPCD conjugate was coated onto the nanoparticle surface via cyclodextrin-benzothiazole host-guest self-assembly. The resulting nanoparticles were characterized by TEM, DLS, zeta potential, FTIR, and TGA. Drug loading, pH-responsive release, cytotoxicity against SMMC-7721 cells, cellular uptake evaluated by confocal microscopy and flow cytometry, and in vivo antitumor efficacy in nude mice were systematically evaluated. BPCD@BAI@BMSN exhibited near-spherical morphology with a particle size of approximately 200 nm, a positive zeta potential of +10 mV, a drug loading of 19.85%, and an encapsulation efficiency of 89.6%. Cumulative baicalin release reached approximately 62% at pH 5.5, whereas only about 6% was released at pH 7.4, confirming acid-triggered gated release. The blank carrier showed no significant cytotoxicity with cell viability above 95%, while drug-loaded nanoparticles exhibited enhanced cytotoxicity at pH 6.8. Biotin-functionalized nanoparticles demonstrated significantly higher cellular uptake and tumor accumulation compared to non-targeted controls. In vivo, BPCD@BAI@BMSN achieved a tumor growth inhibition rate of 72.5% compared to the control group, with no obvious toxicity to major organs observed during the 21-day treatment period. BPCD@BAI@BMSN integrates high drug loading, pH-responsive supramolecular gating, and active tumor targeting into a single nanoplatform, offering a promising strategy for baicalin delivery with enhanced antitumor efficacy and favorable short-term biosafety.

PMID 42763689
Read full article →
PubMedEarth, planets, and space : EPS2026-09-20

Estimation of auroral emission altitude in the region of the ISS magnetic footprint during a relativistic electron precipitation event observed by ISS-CALET.

Yanagisawa Kyutaro K, Kataoka Ryuho R, Seki Kanako K, Whiter Daniel D et al.

We report a multi-MeV relativistic electron precipitation (REP) event as observed by the CALorimetric Electron Telescope and the Monitor of All-sky X-ray Image aboard the International Space Station, together with low-cost twin all-sky auroral imagers installed at Athabasca, Canada. We find that visible auroral emissions near the ISS magnetic footprint during REP events are not frequent-observed in only two of 10 conjugate REP events during our survey period from September 2024 to September 2025-and that one case, on 3 May 2025, featured diffuse aurora near the ISS magnetic footprint. Using two independent stereoscopic methods, we estimate the auroral emission height to be ~90 km, which is typically produced by tens-of-keV electron precipitation. Combined with the MeV electron precipitation detected by CALET, such broadband electron precipitation from tens-of-keV to MeV is consistent with the hypothesis of chorus-driven REP events. The emission altitude shows no systematic latitudinal variation, which is not consistent with field-line curvature scattering type energy-dispersed precipitation. The combined space- and ground-based observations contribute to a better understanding of the spatial context of wave-particle interaction associated with the REP events.

PMID 42763453
Read full article →
PubMedCureus2026-09-20

Five-Year Follow-Up of an Eight-Year-Old Boy With a Scleral-Fixated Carlevale Intraocular Lens After Ocular Trauma.

Drakou Zoi Z, Gotzaridis Stratos S, Kouri Agathi A, Maliagkani Eirini E

Management of pediatric aphakia without capsular support remains challenging, particularly following ocular trauma. Long-term outcomes of sutureless scleral fixation of the Carlevale intraocular lens (IOL) in children remain limited. We present the surgical management and five-year follow-up of a child with traumatic aphakia treated with a Carlevale IOL. An eight-year-old boy sustained a penetrating ocular injury caused by a knife, resulting in a full-thickness corneal laceration, traumatic cataract, and inadequate capsular support. Following primary corneal repair and lens removal elsewhere, the patient was referred to our clinic. A 25-gauge pars plana vitrectomy and sutureless scleral fixation of a Carlevale IOL were performed. At the five-year follow-up examination, the IOL remained well centered without tilt, haptic erosion, or significant inflammatory complications. Visual acuity improved progressively, reaching 0.0 LogMAR without refractive correction at the final examination. This case demonstrates a favorable anatomical and visual outcome at five years following sutureless scleral fixation of a Carlevale IOL in a child with traumatic aphakia and inadequate capsular support. The IOL remained stable at the five-year examination, with excellent uncorrected visual acuity and a favorable refractive outcome. This case suggests a potential role for the Carlevale IOL in the management of pediatric traumatic aphakia.

PMID 42763778
Read full article →
PubMedAcademic pathology2026-09-20

Approaching microaggressions toward ​a career in pathology: A potential path to a respectful culture.

Pleotis Howell Lydia L

PMID 42763510
Read full article →
PubMedCase reports in dermatological medicine2026-09-20

Moxifloxacin-Induced Bullous Acute Generalized Exanthematous Pustulosis (AGEP): A Case Report of a Rare Clinical Presentation.

Yeral Mehmet M, Dasgin Dilek D, Aydogdu Ceyda Tetik CT, Altinbas Ekin E et al.

Acute generalized exanthematous pustulosis (AGEP) is a severe cutaneous adverse reaction (SCAR) typically characterized by sterile pustules. The bullous variant of AGEP is exceptionally rare and represents a significant diagnostic challenge as it clinically mimics toxic epidermal necrolysis (TEN). We report the case of a 91-year-old woman who developed AGEP following moxifloxacin therapy, which rapidly progressed into a bullous form. A striking and rarely described clinical phenomenon-pustules developing directly on the roof of flaccid bullae-was observed. To our knowledge, this is the first reported case of the bullous variant of AGEP specifically triggered by moxifloxacin. Despite intensive treatment, the patient succumbed to sepsis on Day 15. This case underscores the importance of recognizing atypical AGEP presentations to avoid diagnostic confusion with Stevens-Johnson syndrome (SJS)/TEN and highlights a novel severe reaction to a widely used fluoroquinolone.

PMID 42763513
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about meningococcal A conjugate vaccine